CUTIA-B(02487),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02487 CUTIA-B

Market Closed 03-21 16:08:23

5.900

-0.500

-7.81%

High6.400	Low5.820	Vol3.00M
Open6.400	D1 Closing6.400	Amplitude9.06%
Mkt Cap1.88B	Tradable Cap1.88B	Total Shares319.00M
T/O18.04M	T/O Rate0.94%	Tradable Shares319.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"02487","market":"HK","secType":"STK","nameCN":"CUTIA-B","latestPrice":5.9,"timestamp":1742544503031,"preClose":6.4,"halted":0,"volume":2996600,"delay":0,"floatShares":319000000,"shares":319000000,"eps":-10.280709934145563,"marketStatus":"Market Closed","change":-0.5,"latestTime":"03-21 16:08:23","open":6.4,"high":6.4,"low":5.82,"amount":18042288,"amplitude":0.090625,"askPrice":5.9,"askSize":17600,"bidPrice":5.84,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-1.8403589375821237,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1742779800000},"marketStatusCode":7,"adr":0,"listingDate":1686499200000,"exchange":"SEHK","adjPreClose":6.4,"openAndCloseTimeList":[[1742520600000,1742529600000],[1742533200000,1742544000000]],"volumeRatio":1.237538303909068,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02487","defaultTab":"news","newsList":[{"id":"2495631675","title":"Cutia Therapeutics Completes Trial of Adipose Accumulation Drug to Show Safety, Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2495631675","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495631675?lang=en_us&edition=full_marsco","pubTime":"2024-12-31 12:13","pubTimestamp":1735618395,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (HKG:2487) has completed the phase II clinical trial of CU-20401 for submental adipose accumulation in China, a Tuesday bourse filing said.The clinical trial has shown significant and robust efficacy advantages with a favorable safety profile.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","02487","LENZ","BK1161"],"gpt_icon":0},{"id":"2491340311","title":"Sa Sa International CFO Resigns; Successor Named","url":"https://stock-news.laohu8.com/highlight/detail?id=2491340311","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491340311?lang=en_us&edition=full_marsco","pubTime":"2024-12-13 18:26","pubTimestamp":1734085572,"startTime":"0","endTime":"0","summary":"Danny Ho resigned as chief financial officer and an executive director of Sa Sa International  after he accepted a role at another organization, a Friday bourse filing said.Ho was succeeded by Kit Chung, who joined the beauty products retailer as its new CFO on Dec. 2.Before joining the company, Chung worked in an international accounting firm and other companies listed on the Hong Kong and Singapore bourses. He is currently an independent non-executive director of Cutia Therapeutics .","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02487","BK1602","BK1577","BK1502","BK1224","BK1525","00178","BK1601"],"gpt_icon":0},{"id":"2487158973","title":"Cutia Therapeutics Obesity Drug Reaches Meaningful End to Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2487158973","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487158973?lang=en_us&edition=full_marsco","pubTime":"2024-11-29 15:31","pubTimestamp":1732865474,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics  said the Phase II clinical trial of CU-20401 for treating submental adipose accumulation reached its primary endpoint with statistically significant and clinically meaningful outcomes, according to a Friday filing with the Hong Kong bourse.CU-20401 is a recombinant mutant collagenase aiming to counter obesity, overweight, or other localized adipose accumulation-associated metabolic diseases, the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","LENZ","02487","BK4139"],"gpt_icon":0},{"id":"2486364670","title":"Cutia Therapeutics Phase III Trial for Skin Treatments Presented in Annual CDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2486364670","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486364670?lang=en_us&edition=full_marsco","pubTime":"2024-11-28 15:01","pubTimestamp":1732777312,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics  said the Phase III clinical trial in China of CU-40102, a topical finasteride spray, and CU-30101, a localized topical lidocaine and tetracaine cream, was presented through electronic posters at the 19th Annual Meeting of China Dermatologist Association & National Congress of Cosmetic Dermatology, according to a Thursday filing with the Hong Kong bourse.Topical finasteride spray is used for the treatment of androgenetic alopecia, also known as male pattern baldness. CU-30101 is used for localized topical lidocaine and tetracaine cream for surface dermatologic issues, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","III","LENZ","BK4139","02487","BK4134"],"gpt_icon":0},{"id":"2484166232","title":"Cutia Therapeutics CEO Buys More Company Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2484166232","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484166232?lang=en_us&edition=full_marsco","pubTime":"2024-11-18 10:11","pubTimestamp":1731895901,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics  said its chief executive officer, Zhang Lele, acquired 5,200 company shares in the open market on Nov. 14 for about HK$49,604, according to a Monday filing with the Hong Kong bourse.Before this purchase, Zhang purchased a total of 33,000 shares in the open market for a total of about HK$393,212.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK1161","02487"],"gpt_icon":0},{"id":"2482120745","title":"Cutia Therapeutics' Topical Acne Treatment Gets China Marketing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2482120745","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482120745?lang=en_us&edition=full_marsco","pubTime":"2024-11-12 13:28","pubTimestamp":1731389310,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics  said its topical 4% minocycline foam obtained marketing approval from China's National Medical Products Administration, according to a Tuesday filing with the Hong Kong bourse.The topical treatment is used to treat patients as young as nine and adults with non-nodular moderate to severe acne vulgaris, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02487","LENZ","BK4139","BK1161"],"gpt_icon":0},{"id":"2482794181","title":"BRIEF-Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2482794181","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482794181?lang=en_us&edition=full_marsco","pubTime":"2024-11-12 09:21","pubTimestamp":1731374510,"startTime":"0","endTime":"0","summary":"BRIEF-Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPANov 12 (Reuters) - Cutia Therapeutics 2487.HK:CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) OBTAINED MARKETING APPROVAL BY NMPAFurther company coverage: 2487.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MI26Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02487"],"gpt_icon":0},{"id":"2482876149","title":"Cutia Therapeutics - Cu-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2482876149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482876149?lang=en_us&edition=full_marsco","pubTime":"2024-11-12 06:05","pubTimestamp":1731362753,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nFWN3MI26Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02487"],"gpt_icon":0},{"id":"2482211284","title":"Cutia Therapeutics CEO Increase Shareholding in Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2482211284","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482211284?lang=en_us&edition=full_marsco","pubTime":"2024-11-11 08:45","pubTimestamp":1731285939,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics  said its chief executive officer, Zhang Lele, purchased 5,000 shares of the company through the open market for HK$49,280, according to a Monday filing with the Hong Kong bourse.Zhang also bought 28,000 shares of the company in October for HK$343,932 and has not ruled out the possibility of further purchases.These aggregate purchases of shares stood at 33,000 shares for a total of HK$393,212, with an average price of about HK$11.916 per share.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","LENZ","BK4139","02487"],"gpt_icon":0},{"id":"2481528538","title":"Insider Buyers Lose Additional CN¥234k As Cutia Therapeutics Dips To HK$3.5b","url":"https://stock-news.laohu8.com/highlight/detail?id=2481528538","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481528538?lang=en_us&edition=full_marsco","pubTime":"2024-11-05 07:21","pubTimestamp":1730762496,"startTime":"0","endTime":"0","summary":"The recent 11% drop in Cutia Therapeutics' ( HKG:2487 ) stock could come as a blow to insiders who purchased CN¥1.51m...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2487/cutia-therapeutics-shares/news/insider-buyers-lose-additional-cn234k-as-cutia-therapeutics","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02487","BK1161","LENZ","CN","BK4139"],"gpt_icon":0},{"id":"2479700670","title":"Cutia Therapeutics' Phase 2 Trial of Drug for Adipose Accumulation-Related Diseases Complete Database Lock","url":"https://stock-news.laohu8.com/highlight/detail?id=2479700670","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479700670?lang=en_us&edition=full_marsco","pubTime":"2024-10-31 19:36","pubTimestamp":1730374583,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics' (HKG:2487) phase II clinical trial of CU-20401 for submental adipose accumulation has completed database lock, a Thursday bourse filing said.CU-20401 targets obesity, overweightedness, or other localized adipose accumulation-associated metabolic diseases.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02487","BK1161","LENZ","BK4139"],"gpt_icon":0},{"id":"2479707949","title":"Cutia Therapeutics Records 130% Higher Revenue from Commercialized Products in Nine Months to September","url":"https://stock-news.laohu8.com/highlight/detail?id=2479707949","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479707949?lang=en_us&edition=full_marsco","pubTime":"2024-10-31 19:29","pubTimestamp":1730374168,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (HKG:2487) recorded a revenue of 148.9 million from its commercialized products for the nine months ended Sept. 30, representing a year-on-year increase of 129.9%, a Thursday Hong Kong bourse filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02487","LENZ"],"gpt_icon":0},{"id":"2479772807","title":"BRIEF-Cutia Therapeutics Posts 9M Revenue Of Group's Commercialized Products Rmb148.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2479772807","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479772807?lang=en_us&edition=full_marsco","pubTime":"2024-10-31 17:20","pubTimestamp":1730366459,"startTime":"0","endTime":"0","summary":"Oct 31 (Reuters) - Cutia Therapeutics   :   * 9M REVENUE OF GROUP'S COMMERCIALIZED PRODUCTS RMB148.9 MILLIONFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"gpt_icon":0},{"id":"2479745622","title":"Cutia Therapeutics - 9M Revenue of Group's Commercialized Products RMB148.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2479745622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479745622?lang=en_us&edition=full_marsco","pubTime":"2024-10-31 12:01","pubTimestamp":1730347307,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nFWN3M61TY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02487","BK1161"],"gpt_icon":0},{"id":"2476152584","title":"Cutia Therapeutics CEO Acquires 20,000 Shares in Company; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2476152584","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476152584?lang=en_us&edition=full_marsco","pubTime":"2024-10-17 13:06","pubTimestamp":1729141616,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics  said its chief executive officer Zhang Lele purchased 20,000 shares of the company in the open market on Oct. 15 and Oct. 16, according to a Thursday filing with the Hong Kong Bourse.The shares were purchased for HK$241,116 at an average price of about HK$12.056 per share. The filing added that the transactions were carried out using Zhang's personal funds.The company's shares were 5% higher in recent trading.Price : $13.02, Change: $+0.64, Percent Change: +5.17%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4526","02487","BK4139","HKD","BK4588","BK1161","LENZ","BK4585","BK4023"],"gpt_icon":0},{"id":"2476299181","title":"BRIEF-Cutia Therapeutics Announces Increase In Shareholding By CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2476299181","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476299181?lang=en_us&edition=full_marsco","pubTime":"2024-10-17 09:13","pubTimestamp":1729127593,"startTime":"0","endTime":"0","summary":"Oct 17 (Reuters) - Cutia Therapeutics   :   * INCREASE IN SHAREHOLDING BY CHIEF EXECUTIVE OFFICER   * CEO PURCHASED 20,000 SHARES OF CO ON 15 AND 16 OCT FOR HK$241,116Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02487"],"gpt_icon":0},{"id":"2476908001","title":"Cutia Therapeutics -  CEO Purchased 20,000 Shares of Co on 15 and 16 Oct for HK$241,116","url":"https://stock-news.laohu8.com/highlight/detail?id=2476908001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476908001?lang=en_us&edition=full_marsco","pubTime":"2024-10-17 06:06","pubTimestamp":1729116418,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241016:nFWN3LS1CN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02487"],"gpt_icon":0},{"id":"2476080439","title":"Cutia Therapeutics -  Increase in Shareholding by Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2476080439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476080439?lang=en_us&edition=full_marsco","pubTime":"2024-10-17 06:06","pubTimestamp":1729116418,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241016:nFWN3LS1CN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02487","BK1161"],"gpt_icon":0},{"id":"2475096698","title":"Cutia Therapeutics CEO Buys 8,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2475096698","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475096698?lang=en_us&edition=full_marsco","pubTime":"2024-10-14 10:04","pubTimestamp":1728871458,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics'  chief executive officer Zhang Lele purchased a total of 8,000 shares in the open market with her personal funds on Oct. 9 and 10, according to a Monday filing with the Hong Kong bourse.Zhang bought back the shares for a total of HK$102,816, with an average share price of HK$12.85 apiece.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK1161","02487"],"gpt_icon":0},{"id":"2475808329","title":"BRIEF-Cutia Therapeutics Says Increase In Shareholding By CEO And Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2475808329","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475808329?lang=en_us&edition=full_marsco","pubTime":"2024-10-14 09:13","pubTimestamp":1728868401,"startTime":"0","endTime":"0","summary":"Oct 14 (Reuters) - Cutia Therapeutics   :   * INCREASE IN SHAREHOLDING BY CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR   * CEO PURCHASED TOTAL OF 8,000 SHARES ON 9 AND 10 OCTOBER FOR HK$102,816 Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02487"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cutiatx.com","stockEarnings":[{"period":"1week","weight":0.0536},{"period":"1month","weight":0.1049},{"period":"3month","weight":-0.1362},{"period":"6month","weight":-0.5959},{"period":"1year","weight":-0.29},{"period":"ytd","weight":-0.1667}],"compareEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":0.0325},{"period":"3month","weight":0.2013},{"period":"6month","weight":0.2975},{"period":"1year","weight":0.4048},{"period":"ytd","weight":0.1809}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Cutia Therapeutics is a China-based company mainly engaged in the research and development and manufacture of dermatological biological drugs. The Company is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The Company is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The Company conducts its businesses in the domestic market and overseas markets.","exchange":"SEHK","name":"CUTIA-B","nameEN":"CUTIA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CUTIA-B(02487),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CUTIA-B(02487) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CUTIA-B,02487,CUTIA-B股票,CUTIA-B股票老虎,CUTIA-B股票老虎国际,CUTIA-B行情,CUTIA-B股票行情,CUTIA-B股价,CUTIA-B股市,CUTIA-B股票价格,CUTIA-B股票交易,CUTIA-B股票购买,CUTIA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CUTIA-B(02487),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CUTIA-B(02487) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}